Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

Stelljes, 2014, Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis, J Clin Oncol, 32, 288, 10.1200/JCO.2013.50.5768 Thomas, 1982, Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation, Int J Radiat Oncol Biol Phys, 8, 817, 10.1016/0360-3016(82)90083-9 Sorror, 2011, Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies, JAMA, 306, 1874, 10.1001/jama.2011.1558 Bacigalupo, 2009, Defining the intensity of conditioning regimens: working definitions, Biol Blood Marrow Transplant, 15, 1628, 10.1016/j.bbmt.2009.07.004 Bornhäuser, 2012, Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial, Lancet Oncol, 13, 1035, 10.1016/S1470-2045(12)70349-2 Lee, 2013, Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine, J Clin Oncol, 31, 701, 10.1200/JCO.2011.40.2362 Rambaldi, 2015, Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial, Lancet Oncol, 16, 1525, 10.1016/S1470-2045(15)00200-4 Kröger, 2017, Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial), J Clin Oncol, 35, 2157, 10.1200/JCO.2016.70.7349 Scott, 2017, Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, J Clin Oncol, 35, 1154, 10.1200/JCO.2016.70.7091 Clark, 2002, Quantification of the completeness of follow-up, Lancet, 359, 1309, 10.1016/S0140-6736(02)08272-7 Döhner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 129, 424, 10.1182/blood-2016-08-733196 Jagasia, 2015, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 21, 389, 10.1016/j.bbmt.2014.12.001 Rizzo, 2009, Solid cancers after allogeneic hematopoietic cell transplantation, Blood, 113, 1175, 10.1182/blood-2008-05-158782 Panoskaltsis-Mortari, 2011, An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome, Am J Respir Crit Care Med, 183, 1262, 10.1164/rccm.2007-413ST Wingard, 2011, Long-term survival and late deaths after allogeneic hematopoietic cell transplantation, J Clin Oncol, 29, 2230, 10.1200/JCO.2010.33.7212 Socié, 1999, Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry, N Engl J Med, 341, 14, 10.1056/NEJM199907013410103 Sorror, 2011, Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies, JAMA, 306, 1874, 10.1001/jama.2011.1558 Socié, 2001, Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies, Blood, 98, 3569, 10.1182/blood.V98.13.3569 Ringdén, 1999, Blood, 93, 2196, 10.1182/blood.V93.7.2196 Abdul Wahid, 2014, Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis, Stem Cells Dev, 23, 2535, 10.1089/scd.2014.0123 Passweg, 2015, Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group—an observational analysis by the Acute Leukemia Working Party of the EBMT, Bone Marrow Transplant, 50, 1063, 10.1038/bmt.2015.121 Shimoni, 2016, J Hematol Oncol, 9, 118, 10.1186/s13045-016-0347-1 Stelljes, 2005, Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia, Blood, 106, 3314, 10.1182/blood-2005-04-1377 Storb, 2013, Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation, J Clin Oncol, 31, 1530, 10.1200/JCO.2012.45.0247 Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628 Shimoni, 2013, Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced, Leukemia, 27, 829, 10.1038/leu.2012.299 Clift, 1998, Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia, Blood, 92, 1455, 10.1182/blood.V92.4.1455 Mielcarek, 2007, Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors, Biol Blood Marrow Transplant, 13, 1499, 10.1016/j.bbmt.2007.09.004 Blaise, 2013, Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation, Cancer, 119, 602, 10.1002/cncr.27786